Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 6/22/15 → 6/30/17 |
Funding
- Medpace Inc: $6,915.00
ChemoCentryx-A Randomized, Double-Blind, Placebo-Controlled, Dose Assessment Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
- Lohr, Kristine (PI)